Lacunar Stroke Does Not Justify Long-term Dual Antiplatelet Therapy

Hooman Kamel, MD


Journal Watch 

In This Article


Although short-term dual antiplatelet therapy may eventually prove to benefit specific populations with very high stroke risk, the SPS3 trial definitively establishes that lacunar stroke alone is an inappropriate indication for long-term dual antiplatelet therapy. Study participants had meticulous blood pressure control and used statins diligently, which likely contributed to the impressively low rates of recurrent stroke.